In this multicenter , parallel group , non-inferiority study , patients received AML 10 mg during a 2 - to 4-week run-in before randomization to 24 weeks of double-blind treatment with the fixed-dose combination of OLM/AML 40/10 mg or PER/AML 8/10 mg .